行情

ATOS

ATOS

Atossa Therapeutics Inc
NASDAQ

实时行情|Nasdaq Last Sale

1.330
+0.150
+12.71%
盘后: 1.350 +0.02 +1.50% 19:02 03/31 EDT
开盘
1.240
昨收
1.180
最高
1.370
最低
1.200
成交量
26.22万
成交额
--
52周最高
4.260
52周最低
0.7550
市值
1,214.42万
市盈率(TTM)
-0.6448
分时
5日
1月
3月
1年
5年

分析师评级

1位分析师的综合评级

买入

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

目标价格预测

分析师预测ATOS价格均价为4.000,最高价位4.000,最低价为4.000。

EPS

ATOS 新闻

更多
  • 纽约州从中国订购1.7万台呼吸机
  • 央视 · 1小时前
  • 美国2万亿刺激计划流向何处?私募股权公司或成最大输家
  • 新浪美股 · 1小时前
  • 消息称施乐已放弃340亿美元收购惠普要约
  • 新浪科技 · 1小时前
  • "美国徐翔"Steven Cohen呼吁保持谨慎:"地震过后当心余震"
  • 新浪美股 · 2小时前

所属板块

生物技术和医学研究
-0.26%
制药与医学研究
-0.17%

热门股票

代码
价格
涨跌幅

ATOS 简况

Atossa Therapeutics Inc., formerly Atossa Genetics Inc., is a clinical-stage biopharmaceutical company. The Company is focused on developing therapeutics and delivery methods for breast cancer and other breast conditions. Its pipeline includes two programs: endoxifen and intraductal microcatheter technology. It is developing Topical Endoxifen formulation for transdermal delivery. It is developing Topical Endoxifen to address two populations: to reduce mammographic breast density (MBD) and to prevent/reduce gynecomastia in prostate cancer patients starting androgen deprivation therapy. It is also developing oral presentation of endoxifen. It is developing its microcatheter technology to deliver therapeutics through the nipple directly to the site of early breast cancer. It is also developing our proprietary intraductal microcatheter technology for Chimeric Antigen Receptor Therapy (CAR-T).
展开

微牛提供Atossa Therapeutics Inc(NASDAQ-ATOS)的股票价格,实时市场报价,专业分析师评级,深度图表和免费的ATOS股票新闻,以帮助您做出投资决策。